NEW YORK–(BUSINESS WIRE)–Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB). Dr. Fischer is a global leader in targeted protein degradation with appointments at Dana-Farber Cancer Institute (Dana-Farber) and Harvard Medical School. He is also the Director of the Dana-Farber/Deerfield Center for Protein Degradation.
“We are excited to have Eric join our scientific advisory board,” said Dr. Ross Levine, Chair of Ajax’s SAB and Deputy Physician-in-Chief, Translational Research, Laurence Joseph Dineen Chair in Leukemia Research and Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. “I look forward to working with him as we continue to pursue new ways of targeting JAK2 to identify much needed disease modifying therapies for MPN patients.”
“I’m pleased to be joining the Ajax SAB at such an exciting time in the company’s development,” said Dr. Fischer. “I have worked closely with the Ajax team over the past few years and have been impressed by their drug discovery expertise and the world leading JAK experts they have assembled as scientific founders and advisors. I look forward to continuing to interact with this group to develop next-generation approaches to drugging JAK2, including targeted protein degradation.”
Dr. Fischer is an Independent Investigator and Director of the Chemical Biology Program at Dana Farber Cancer Institute and Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Fischer’s research focuses on understanding the molecular architecture, function, and regulation of complex cellular signaling machines and their involvement in cellular processes. His work helping to understand the mechanism of action of Thalidomide and related drugs was critical to establishing the novel therapeutic modality known as targeted protein degradation. Dr. Fischer’s research has been recognized by awards including the Damon Runyon-Rachleff Innovation Award and the Mark Foundation’s Emerging Leaders Award. He is a co-founder of Civetta Therapeutics, Neomorph, Inc. and Proximity Therapeutics. Dr. Fischer completed his undergraduate training at the Universities of Hamburg and Basel and his doctoral training at the Friedrich Miescher Institute for Biomedical Research.
About Ajax Therapeutics
Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), including Myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms from our founding partner, Schrödinger, Inc., we aim to discover and develop more precisely designed therapies to address significant unmet needs for patients with MPNs.
Please find more information at www.ajaxtherapeutics.com.